Welcome to our dedicated page for Syros Pharmaceut news (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceut stock.
Syros Pharmaceuticals (SYRS) is a leader in gene regulation research, developing novel therapies for oncology and hematologic malignancies through its integrated platform of assay technologies and bioinformatics. This page provides centralized access to all official company announcements, press releases, and third-party analyses related to SYRS's scientific advancements and corporate developments.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes updates on SYRS's drug discovery pipeline, financial results, and peer-reviewed research collaborations – all organized for efficient tracking of the company's progress in transforming gene control insights into therapeutic solutions.
Key content categories include clinical trial announcements, FDA regulatory updates, partnership disclosures with academic institutions, quarterly earnings reports, and scientific conference presentations. Each entry is verified for accuracy and relevance to SYRS's core mission of advancing precision medicine through gene regulatory circuit mapping.
Bookmark this page for streamlined monitoring of SYRS's developments in hematologic and oncology research. Check back regularly for authoritative updates on how Syros Pharmaceuticals continues to pioneer new approaches in targeted drug discovery.
Syros Pharmaceuticals (SYRS) reported its first-quarter 2024 financial results and provided a corporate update. The company highlighted passing an interim futility analysis in the Phase 3 SELECT-MDS-1 trial, with pivotal CR data expected by mid-Q4 2024. Additionally, the FDA granted Fast Track designation for Tamibarotene in unfit AML. Financially, Syros recorded no revenue compared to $3 million in Q1 2023, and a net loss of $3.7 million, significantly reduced from $23.8 million the previous year. R&D expenses were $24.7 million, down from $28.8 million, while G&A expenses also decreased from $7.4 million to $6.3 million. The company’s cash position was $108.3 million as of March 31, 2024, sufficient to fund operations into Q3 2025.
Syros Pharmaceuticals (SYRS) will participate in two upcoming investor conferences to discuss advancements in the treatment of hematologic malignancies. The company's management will engage in a fireside chat at the JMP Securities 2024 Life Sciences Conference on May 14 and the TD Cowen’s 5th Annual Oncology Innovation Summit on May 29. Interested parties can access webcasts and archived recordings of the events on the Syros website.
Syros Pharmaceuticals (NASDAQ:SYRS) will report its first quarter 2024 financial results on Tuesday, May 14, 2024, with a live conference call and webcast scheduled. The company aims to advance new standards of care for hematologic malignancies.
FAQ
What is the current stock price of Syros Pharmaceut (SYRS)?
What is the market cap of Syros Pharmaceut (SYRS)?
